Sialic Acids in Pancreatic Cancer Cells Drive Tumor-Associated Macrophage Differentiation via the Siglec Receptors Siglec-7 and Siglec-9

Researchers showed that PDAC tumor cells present an increased sialylation that could be recognized by Siglec-7 and Siglec-9 on myeloid cells.
[Nature Communications]
Rodriguez, E., Boelaars, K., Brown, K., Eveline Li, R. J., Kruijssen, L., Bruijns, S. C. M., van Ee, T., Schetters, S. T. T., Crommentuijn, M. H. W., van der Horst, J. C., van Grieken, N. C. T., van Vliet, S. J., Kazemier, G., Giovannetti, E., Garcia-Vallejo, J. J., & van Kooyk, Y. (2021). Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9. Nature Communications, 12(1), 1270. https://doi.org/10.1038/s41467-021-21550-4 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Expression of Immune Checkpoints on Circulating Tumor Cells in Men with Metastatic Prostate Cancer

Researchers characterized circulating tumor cells for expression of immune checkpoint ligands in men with metastatic prostate cancer as a non-invasive biomarker of immune evasion and immunotherapy benefit.
[Biomarker Research]
Zhang, T., Agarwal, A., Almquist, R. G., Runyambo, D., Park, S., Bronson, E., Boominathan, R., Rao, C., Anand, M., Oyekunle, T., Healy, P., McNamara, M. A., Ware, K., Somarelli, J. A., George, D. J., & Armstrong, A. J. (2021). Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer. Biomarker Research, 9(1), 14. https://doi.org/10.1186/s40364-021-00267-y Cite
Full Article
Bookmark

No account yet? Register

0
Share

Relaxin Gene Delivery Modulates Macrophages to Resolve Cancer Fibrosis and Synergizes with Immune Checkpoint Blockade Therapy

Scientists revealed previously unidentified insights into the modulation of macrophages to regulate tumor-associated fibrosis, providing a feasible strategy to reverse the immunosuppressive environment and improve the therapeutic outcome of checkpoint immunotherapies.
[Science Advances]
Zhou, X., Liu, Y., Hu, M., Wang, M., Liu, X., & Huang, L. (2021). Relaxin gene delivery modulates macrophages to resolve cancer fibrosis and synergizes with immune checkpoint blockade therapy. Science Advances, 7(8), eabb6596. https://doi.org/10.1126/sciadv.abb6596 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Combination Therapy with iRGD-antiCD3 and PD-1 Blockade Enhances Antitumor Potency of Cord Blood-Derived T Cells

Scientists detected the levels of both PD-1 and PD-L1 as resistance to iRGD-antiCD3 treatment. Using cord blood-derived T cells, they assessed the activation and effects of iRGD-antiCD3 combined with PD-1 as evidenced by activation markers, Th1/Th2-cytokines, and killing capability against tumor cells in vitro.
[Oncotargets and Therapy]
Zhu, M., Wang, H., Zhou, S., Wei, J., Ding, N., Shao, J., Yu, L., Feng, Z., & Liu, B. (2021, February 5). <p>Combination Therapy with iRGD-antiCD3 and PD-1 Blockade Enhances Antitumor Potency of Cord Blood-Derived T Cells</p>. OncoTargets and Therapy. https://doi.org/10.2147/OTT.S291086 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Targeting IL-21 to Tumor-Reactive T Cells Enhances Memory T Cell Responses and Anti-PD-1 Antibody Therapy

Researchers demonstrated that IL-21 could be targeted to tumor-reactive T cells by fusion of IL-21 to anti-PD-1 antibody.
[Nature Communications]
Li, Y., Cong, Y., Jia, M., He, Q., Zhong, H., Zhao, Y., Li, H., Yan, M., You, J., Liu, J., Chen, L., Hang, H., & Wang, S. (2021). Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy. Nature Communications, 12(1), 951. https://doi.org/10.1038/s41467-021-21241-0 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Lee’s Pharmaceutical Announces Its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, Receives Breakthrough Therapy Designation in China for the Treatment of Recurrent or Metastatic Cervical Cancer

China Oncology Focus Limited an affiliate of Lee’s Pharmaceutical Holdings Limited, and Sorrento Therapeutics, Inc. announced that its anti-PD-L1 antibody, socazolimab, licensed from Sorrento to COF for the greater China territory, has been granted breakthrough therapy designation by the China National Medical Products Administration to treat recurrent or metastatic cervical cancer.
[Lee’s Pharmaceutical (Globe Newswire, Inc.)]
Press Release
Bookmark

No account yet? Register

0
Share

HDAC Inhibition Potentiates Anti-tumor Activity of Macrophages and Enhances Anti-PD-L1-Mediated Tumor Suppression

Scientists demonstrated that low-dose HDAC inhibitor trichostatin-A markedly reshaped the tumor immune microenvironment by modulating the suppressive activity of infiltrating macrophages and inhibiting the recruitment of myeloid-derived suppressor cells in various tumors.
[Oncogene]
Li, X., Su, X., Liu, R., Pan, Y., Fang, J., Cao, L., Feng, C., Shang, Q., Chen, Y., Shao, C., & Shi, Y. (2021). HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression. Oncogene, 1–15. https://doi.org/10.1038/s41388-020-01636-x Cite
Full Article
Bookmark

No account yet? Register

0
Share

Mesenchymal Stromal Cell Delivery of Oncolytic Immunotherapy Improves CAR-T Cell Antitumor Activity

The authors describe how MSCs can be used to systemically deliver a binary vector containing an oncolytic adenovirus (Ad) together with a helper dependent Ad that expresses IL-12 and checkpoint PD-L1 blocker.
[Molecular Therapy]
McKenna, M. K., Englisch, A., Brenner, B., Smith, T., Hoyos, V., Suzuki, M., & Brenner, M. K. (2021). Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity. Molecular Therapy, 0(0). https://doi.org/10.1016/j.ymthe.2021.02.004 Cite
AbstractGraphical Abstract
Bookmark

No account yet? Register

0
Share

Adjuvant Treatment with Opdivo (Nivolumab) Demonstrates Statistically Significant and Clinically Meaningful Improvement in Disease-Free Survival in Patients with Muscle-Invasive Urothelial Carcinoma in Phase III CheckMate -274 Trial

Bristol Myers Squibb announced results from the Phase III CheckMate -274 trial, which showed that Opdivo significantly improved disease-free survival as an adjuvant treatment across all randomized patients with surgically resected, high-risk muscle-invasive urothelial carcinoma and in the subgroup of patients whose tumors express PD-L1 ≥1%, meeting both of the study’s primary endpoints.
[Bristol Myers Squibb]
Press Release
Bookmark

No account yet? Register

0
Share

PDS Biotech Announces Preliminary Efficacy Achievement in Phase II Combination Trial of PDS0101 Led by the National Cancer Institute

PDS Biotechnology Corporation announced that the National Cancer Institute’s (NCI) Phase II clinical study of PDS0101 for the treatment of advanced human papillomavirus-associated cancers that have progressed or returned after treatment achieved its preliminary objective response.
[PDS Biotechnology Corporation (Globe Newswire, Inc.)]
Press Release
Bookmark

No account yet? Register

0
Share

Laminin γ2–Mediating T Cell Exclusion Attenuates Response to anti–PD-1 Therapy

The up-regulation of laminin γ2 predicted the attenuated efficacy of anti–PD-1 drugs and was associated with unfavorable outcomes in patients with lung cancer or esophageal cancer.
[Science Advances]
Li, L., Wei, J.-R., Dong, J., Lin, Q.-G., Tang, H., Jia, Y.-X., Tan, W., Chen, Q.-Y., Zeng, T.-T., Xing, S., Qin, Y.-R., Zhu, Y.-H., Li, Y., & Guan, X.-Y. (2021). Laminin γ2–mediating T cell exclusion attenuates response to anti–PD-1 therapy. Science Advances, 7(6), eabc8346. https://doi.org/10.1126/sciadv.abc8346 Cite
Full Article
Bookmark

No account yet? Register

0
Share
Share